FILE 'HCAPLUS' ENTERED AT 10:00:29 ON 25 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:00:29 ON 25 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d his

(FILE 'HOME' ENTERED AT 09:46:20 ON 25 JAN 2004)

FILE 'REGISTRY' ENTERED AT 09:58:48 ON 25 JAN 2004
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 1 S L1 SSS FULL

FILE 'HCAPLUS, USPATFULL' ENTERED AT 09:59:44 ON 25 JAN 2004
L4 6 S L3

FILE 'REGISTRY' ENTERED AT 09:59:59 ON 25 JAN 2004
L5 1 DUP REM L3 (0 DUPLICATES REMOVED)

FILE 'HCAPLUS, USPATFULL' ENTERED AT 10:00:29 ON 25 JAN 2004

=> dup rem l4
PROCESSING COMPLETED FOR L4
L6 3 DUP REM L4 (3 DUPLICATES REMOVED)

=> d l6 abs ibib hitstr 1-3

L6 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
GI



I

AB Title compds., e.g. [I; R = O2CR1; R1 = alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkylalkyl, heterocyhcloalkyl, heterocycloalkyl, (substituted) Ph, PhNH, PhCH2, etc.], were prepd. Thus, Me 2-amino-5-hydroxybenzimidazole carbamate and 3,5,5-trimethylhexanoyl chloride were stirred in THF at 23-40.degree. to give I (R = O2CCH2CHMeCH2CMe3). The latter inhibited human colon carcinoma with IC50 = 15.8 .mu.M.

ACCESSION NUMBER: 2002:889200 HCAPLUS
DOCUMENT NUMBER: 137:370090
TITLE: Preparation of benzimidazolecarbamates for treatment of cancer or viral infections
INVENTOR(S): Quada, James C., Jr.; Agyin, Joseph K.; Camden, James

Berger
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S., 20 pp., Cont.-in-part of U.S. Ser. No. 857,811.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6482843	B1	20021119	US 2000-676407	20000929
US 6506783	B1	20030114	US 1997-857811	19970516
BR 9714634	A	20000523	BR 1997-14634	19971126
CN 1254282	A	20000524	CN 1997-182190	19971126
US 6077862	A	20000620	US 1999-259969	19990301
AU 763272	B2	20030717	AU 2001-37094	20010418

PRIORITY APPLN. INFO.: US 1997-857811 A2 19970516
AU 1998-74027 A3 19971126
WO 1997-US24565 W 19971126

OTHER SOURCE(S): MARPAT 137:370090

IT **443685-81-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzimidazolecarbamates for treatment of cancer or viral infections)

RN 443685-81-2 HCAPLUS
CN Hexanoic acid, 3,5,5-trimethyl-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-4-yl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 106 THERE ARE 106 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
GI



I



II

DELACROIX

AB The title compds. [I (R = OCORa; Ra = (un)substituted Ph), II (R = CONR1R2, CO2R1, OCOR1, NHCOR1; R1 = alkyl, haloalkyl, cycloalkyl, etc.; R2 = H, alkyl)] were prepd. Thus, reacting Me 2-amino-5-hydroxybenzimidazolecarbamate with 3,5,5-trimethylhexanoyl chloride in THF afforded 57% I [R = OCOCH2CHMeCH2CMe3] which showed IC50 of 20.1 .mu.M and IC50 of 15.8 .mu.M for growth inhibition of B16 murine melanoma cells and H29 human colon cancer cells, resp. Such compds. I may be used in combination with a chemotherapeutic agent and/or a potentiator.

ACCESSION NUMBER: 2002:551611 HCAPLUS
DOCUMENT NUMBER: 137:109276
TITLE: Preparation of methyl 1H-benzimidazole-2-carbamates for treating cancer or viral infections
INVENTOR(S): Camden, James Berger; Agyin, Joseph K.; Quada, James C., Jr.
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S., 19 pp., Cont. of U.S. Ser. No. 857,811., CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6423736	B1	20020723	US 2000-676409	20000929
US 6506783	B1	20030114	US 1997-857811	19970516
BR 9714634	A	20000523	BR 1997-14634	19971126
CN 1254282	A	20000524	CN 1997-182190	19971126
US 6077862	A	20000620	US 1999-259969	19990301
AU 763272	B2	20030717	AU 2001-37094	20010418

PRIORITY APPLN. INFO.: US 1997-857811 A2 19970516
AU 1998-74027 A3 19971126
WO 1997-US24565 W 19971126

OTHER SOURCE(S): MARPAT 137:109276

IT **443685-81-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of Me benzimidazole-2-carbamates for treating cancer or viral infections)

RN 443685-81-2 HCAPLUS
CN Hexanoic acid, 3,5,5-trimethyl-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-4-yl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 119 THERE ARE 119 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3
GI



I II

AB The title compds. [I (R = OCORa; Ra = (un)substituted Ph), II (R = CONR1R2, CO2R1, OCOR1, NHCOR1; R1 = alkyl, haloalkyl, cycloalkyl, etc.; R2 = H, alkyl)] were prepd. Thus, reacting Me 2-amino-5-hydroxybenzimidazolecarbamate with 3,5,5-trimethylhexanoyl chloride in THF afforded 57% I [R = OCOCH2CHMeCH2CMe3] which showed IC50 of 20.1 .mu.M and IC50 of 15.8 .mu.M for growth inhibition of B16 murine melanoma cells and H29 human colon cancer cells, resp. Such compds. I may be used in combination with a chemotherapeutic agent and/or a potentiator such as DNA-interactive agent, an antimetabolite, a tubulin-interactive agent, a hormonal agent, an antihormonal antigen, and an adrenal corticosteroid.

ACCESSION NUMBER: 2002:551610 HCAPLUS
DOCUMENT NUMBER: 137:109275
TITLE: Preparation of methyl 1H-benzimidazole-2-carbamates for treating cancer or viral infections
INVENTOR(S): Camden, James Berger; Quada, James C., Jr.; Agyin, Joseph K.
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: U.S., 17 pp., Cont. of U.S. Ser. No. 857,811.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6423735	B1	20020723	US 2000-676029	20000929
US 6506783	B1	20030114	US 1997-857811	19970516
BR 9714634	A	20000523	BR 1997-14634	19971126
CN 1254282	A	20000524	CN 1997-182190	19971126
US 6077862	A	20000620	US 1999-259969	19990301
AU 763272	B2	20030717	AU 2001-37094	20010418

PRIORITY APPLN. INFO.: US 1997-857811 A2 19970516
AU 1998-74027 A3 19971126
WO 1997-US24565 W 19971126

OTHER SOURCE(S): MARPAT 137:109275

IT **443685-81-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of Me benzimidazole-2-carbamates for treating cancer or viral infections)

RN 443685-81-2 HCAPLUS
CN Hexanoic acid, 3,5,5-trimethyl-, 2-[(methoxycarbonyl)amino]-1H-benzimidazol-4-yl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT